Tampa General Hospital adopts LIBERTY endovascular robotic system

Microbot Medical Inc., developer and distributor of the LIBERTY Endovascular Robotic System, announced that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY robotic surgical system.

The company said that this marks another milestone, following its FDA 510(k) clearance.

Growing deployments of robotic surgical tools

Microbot believes that this reflects early post-clearance momentum for LIBERTY and highlights growing institutional readiness for advanced robotic technologies in peripheral endovascular procedures. Microbot said that the U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually, representing a significant and expanding clinical and commercial opportunity.

“As the first health system in Florida to adopt LIBERTY, we are advancing our commitment to leading-edge technology that has the potential to meaningfully transform how care is delivered,” said Dr. Jean Bismuth, division chief of vascular surgery for the University of South Florida Morsani College of Medicine and medical director, TGH Heart & Vascular Institute. “LIBERTY brings sophisticated robotic capabilities to the endovascular space, allowing us to extend advanced innovation directly to our patients. It also has the potential to protect the long-term health of our physicians by addressing growing concerns around radiation safety and ergonomic strain.”

Tampa General is a nationally ranked research and academic medical center affiliated with the University of South Florida. TGH utilizes various types of robotic medical and surgical technologies.

“Tampa General Hospital’s strong culture of innovation and clinical leadership makes them an ideal partner as the first health system in Florida to adopt LIBERTY,” said Harel Gadot, CEO, president & chairman of Microbot Medical. “We believe that this serves as a powerful endorsement of LIBERTY’s differentiated value and market relevance.”

Microbot said that LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026.